RxDoctor Payments Data

Ramesh Krishnamurthi, MD

Internal Medicine · North Canton, OHNPI 1891762365

Payments from drug & device makers

$3,144in general payments, 2019–2025

Across 89 payments — averaging $35.33 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Antares Pharma, Inc.$655
  • Boston Scientific$629
  • Endo Pharmaceuticals Inc.$410
  • Coloplast$337
  • Endo USA, Inc.$133
  • Teleflex LLC$123
  • plus $857 from 17 others

What the payments were for

  • Food & beverage$3,144100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$3,144 in reported general payments places this provider in the 85th percentile of 4,428 internal medicine providers in Ohio.

See all internal medicine providers in Ohio

Medicare billing

Part B allowed, 2024
$70,706
Medicare patients
405
Services billed
906

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Tamsulosin Hcl1,005$15,112
MyrbetriqMirabegron20$13,086
Finasteride325$6,085
Solifenacin Succinate82$4,406
Trospium Chloride56$3,308
Trospium Chloride ErTrospium Chloride14$3,110
Testosterone19$2,973
Tadalafil16$2,090
Testosterone Cypionate40$1,680
Oxybutynin Chloride ErOxybutynin Chloride60$1,557
Tolterodine Tartrate ErTolterodine Tartrate24$1,140
Dutasteride14$1,013
Alfuzosin Hcl ErAlfuzosin Hcl41$926
Rosuvastatin Calcium13$403
Clotrimazole-BetamethasoneClotrimazole/Betamethasone Dip11$258

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Astellas Pharma US IncMyrbetriq$123$13,08620 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 4,428 internal medicine providers in Ohio.

Other internal medicine in North Canton

See the full list for Ohio

Where these figures come from

Is this you, or does something look wrong? →